FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

NAD+ Restoration

Anti-Aging & Longevitybeginner

76

协同作用

76
Share
肽类

2

平均每日mcg

76,429

级别

beginner

添加时间

May 17, 2026

概述

The NAD+ Restoration stack combines senolytic therapy with direct NAD+ replenishment to address two interconnected hallmarks of aging: cellular senescence and metabolic cofactor depletion. FOXO4-DRI is a D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus of senescent cells, preventing them from undergoing apoptosis. By competitively binding FOXO4, the DRI peptide frees p53 to trigger apoptotic pathways specifically in senescent cells — those dysfunctional cells that accumulate with age and secrete inflammatory factors (SASP) that damage surrounding healthy tissue. In the landmark 2017 study by Baar et al. published in Cell, FOXO4-DRI administration to aged mice restored fitness, fur density, and renal function by selectively clearing senescent cells. This represents a true senolytic mechanism — killing aged cells rather than trying to rejuvenate them. The D-retro-inverso modification makes the peptide resistant to proteolytic degradation, giving it extended biological activity. NAD+ intravenous infusion provides direct restoration of this critical coenzyme, bypassing the multi-step oral conversion pathway (NMN → NAD+ requires enzymatic steps that may be rate-limited in aging tissues). NAD+ is required for sirtuin activation (SIRT1-7), PARP-mediated DNA repair, mitochondrial electron transport, and circadian clock function. The combination logic is that clearing senescent cells (FOXO4-DRI) removes the source of inflammatory signaling that depletes NAD+ in neighboring cells, while NAD+ infusion restores the metabolic capacity of remaining healthy cells. This represents a cutting-edge research protocol — FOXO4-DRI has no human clinical trials, and the stack should be understood as experimental and hypothesis-driven.

给药方案

FOXO4-DRI

2x/week· subcutaneous

了解更多关于FOXO4-DRI →

5,000 mcg

每剂

NAD+ (IV)

Once per week· intravenous

了解更多关于NAD+ (IV) →

500,000 mcg

每剂

目标与证据

Senescent cell clearanceNAD levelsCellular energyAnti-agingSenolytic
证据等级:动物研究

警告

  • FOXO4-DRI is highly experimental with no human trials. NAD+ IV therapy is widely available but expensive. This is a cutting-edge research stack.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。